Treatment outcome of patients with smear-negative and smear-positive pulmonary tuberculosis in the National Tuberculosis Control Programme, Malawi
- 1 July 1999
- journal article
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 93 (4) , 443-446
- https://doi.org/10.1016/s0035-9203(99)90153-0
Abstract
National tuberculosis control programmes (NTPs) in sub-Saharan Africa do not routinely record or report treatment outcome data on smear-negative pulmonary tuberculosis (PTB) patients. Twelve-month treatment outcome on patients with smear-negative PTB registered in all district and mission hospitals in Malawi during the year 1995 was collected, and was compared with 8-month treatment outcome in smear-positive PTB patients registered during the same period. Of 4240 patients with smear-negative PTB, 35% completed treatment, 25% died, 9% defaulted and 7% were transferred to another district with no treatment outcome results available. In 24% of patients treatment cards were lost and treatment outcome was unknown. These results were significantly inferior to those obtained in 4003 patients with smear-positive PTB in whom 72% completed treatment, 20% died, 4% defaulted, 2% were transferred and 1% had positive smears at the end of treatment. These differences between patients with smear-negative and smear-positive PTB were similar when analysed by sex and by most age-groups. Higher mortality rates in patients with smear-negative PTB are probably attributable to advanced HIV-related immunosuppression, and higher default and treatment unknown rates probably reflect the lack of attention paid by TB programme staff to this group of patients. As a result of this country-wide study the Malawi NTP has started to record routinely the treatment outcomes of smear-negative TB patients and has set treatment completion targets of 50% or higher for this group of patients.Keywords
This publication has 9 references indexed in Scilit:
- Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba hospital, MalawiTransactions of the Royal Society of Tropical Medicine and Hygiene, 1998
- Pulmonary Tuberculosis in HIV-Infected Patients in Zaire — A Controlled Trial of Treatment for Either 6 or 12 MonthsNew England Journal of Medicine, 1995
- Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'IvoireThe Lancet, 1995
- Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected UgandansThe Lancet, 1994
- Tuberculosis and HIV infection in sub-Saharan AfricaJAMA, 1992
- Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosisThe Lancet, 1991
- Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, KenyaThe Lancet, 1990
- Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in east Africa third report of fifth investigationTubercle, 1973
- Streptomycin plus thiacetazone (thioacetazone*) compared with streptomycin plus pas and with isoniazid plus thiacetazone in the treatment of pulmonary tuberculosis in rhodesiaTubercle, 1968